<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">ARYA Atheroscler</journal-id><journal-id journal-id-type="iso-abbrev">ARYA Atheroscler</journal-id><journal-id journal-id-type="publisher-id">ARYA</journal-id><journal-title-group><journal-title>ARYA Atherosclerosis</journal-title></journal-title-group><issn pub-type="ppub">1735-3955</issn><issn pub-type="epub">2251-6638</issn><publisher><publisher-name>Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24575134</article-id><article-id pub-id-type="pmc">3933059</article-id><article-id pub-id-type="publisher-id">ARYA-09-326</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Clinical investigation of the acute effects of pomegranate juice on blood pressure and endothelial function in hypertensive individuals</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Asgary</surname><given-names>Sedigheh</given-names></name><xref ref-type="aff" rid="af1-ARYA-09-326">1</xref><xref rid="c1-ARYA-09-326" ref-type="corresp"></xref></contrib><contrib contrib-type="author"><name><surname>Keshvari</surname><given-names>Mahtab</given-names></name><xref ref-type="aff" rid="af2-ARYA-09-326">2</xref></contrib><contrib contrib-type="author"><name><surname>Sahebkar</surname><given-names>Amirhossein</given-names></name><xref ref-type="aff" rid="af3-ARYA-09-326">3</xref></contrib><contrib contrib-type="author"><name><surname>Hashemi</surname><given-names>Mohamad</given-names></name><xref ref-type="aff" rid="af4-ARYA-09-326">4</xref></contrib><contrib contrib-type="author"><name><surname>Rafieian-Kopaei</surname><given-names>Mahmoud</given-names></name><xref ref-type="aff" rid="af5-ARYA-09-326">5</xref></contrib></contrib-group><aff id="af1-ARYA-09-326"><label>1</label>Professor, Isfahan Cardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="af2-ARYA-09-326"><label>2</label>Isfahan Cardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="af3-ARYA-09-326"><label>3</label>Assistant Professor, Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran</aff><aff id="af4-ARYA-09-326"><label>4</label>Cardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="af5-ARYA-09-326"><label>5</label>Professor, Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran</aff><author-notes><corresp id="c1-ARYA-09-326">Correspondence to: Sedigheh Asgary, Email: <email xlink:href="sasgary@yahoo.com">sasgary@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2013</year></pub-date><volume>9</volume><issue>6</issue><fpage>326</fpage><lpage>331</lpage><history><date date-type="received"><day>11</day><month>4</month><year>2013</year></date><date date-type="accepted"><day>20</day><month>7</month><year>2013</year></date></history><permissions><copyright-statement>© 2013 Isfahan Cardiovascular Research Center &amp; Isfahan University of Medical Sciences</copyright-statement><copyright-year>2013</copyright-year><license xlink:href="http://creativecommons.org/licenses/by-nc/3.0/" license-type="open-access"><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="4098" xml_f="4108" txt_i="11" txt_f="21">BACKGROUND</offsets></title><p><offsets xml_i="4119" xml_f="4371" txt_i="22" txt_f="274">Pomegranate juice (PJ) is rich in bioactive phytochemicals with antioxidant, and anti-inflammatory and cardioprotective functions. The present trial investigated the acute effects of PJ consumption on blood pressure and markers of endothelial function.</offsets></p></sec><sec id="st2"><title><offsets xml_i="4402" xml_f="4409" txt_i="276" txt_f="283">METHODS</offsets></title><p><offsets xml_i="4420" xml_f="4933" txt_i="284" txt_f="797">In this single-arm study, thirteen hypertensive men aged 39-68 years were recruited. Included subjects were assigned to natural PJ (150 ml/day) following a 12 hour fast. Systolic blood pressure (SBP), diastolic blood pressure (DBP), and flow-mediated dilation (FMD), along with serum concentrations of C-reactive protein (CRP), intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), E-selectin and interleukin-6 (IL-6) were measured at baseline and 4-6 hours after PJ consumption.</offsets></p></sec><sec id="st3"><title><offsets xml_i="4964" xml_f="4971" txt_i="799" txt_f="806">RESULTS</offsets></title><p><offsets xml_i="4982" xml_f="5268" txt_i="807" txt_f="1090">Comparison of pre- vs. post-trial values revealed a significant reduction in both SBP (7%; P = 0.013) and DBP (6%; P &lt; 0.010). However, changes in FMD (20%) as well as circulating levels of CRP, ICAM-1, VCAM-1, E-selectin, and IL-6 did not reach statistical significance (P = 0.172).</offsets></p></sec><sec id="st4"><title><offsets xml_i="5299" xml_f="5309" txt_i="1092" txt_f="1102">CONCLUSION</offsets></title><p><offsets xml_i="5320" xml_f="5487" txt_i="1103" txt_f="1270">PJ has promising acute hypotensive properties. Consumption of PJ could be considered in the context of both dietary and pharmacological interventions for hypertension.</offsets></p></sec></abstract><kwd-group><kwd>Punica Granatum L.</kwd><kwd>Cardiovascular Disease</kwd><kwd>Hypertension</kwd><kwd>Inflammation</kwd><kwd>Endothelium-Dependent Dilation</kwd></kwd-group></article-meta></front><body><sec><title><offsets xml_i="5721" xml_f="5733" txt_i="1279" txt_f="1291">Introduction</offsets></title><p><offsets xml_i="5744" xml_f="5835" txt_i="1292" txt_f="1383">Cardiovascular disorders are among the leading causes of death and disability in the world.</offsets><xref rid="b1-ARYA-09-326" ref-type="bibr"><offsets xml_i="5878" xml_f="5879" txt_i="1383" txt_f="1384">1</offsets></xref><offsets xml_i="5886" xml_f="5887" txt_i="1384" txt_f="1385">,</offsets><xref rid="b2-ARYA-09-326" ref-type="bibr"><offsets xml_i="5930" xml_f="5931" txt_i="1385" txt_f="1386">2</offsets></xref><offsets xml_i="5938" xml_f="6194" txt_i="1386" txt_f="1642"> Hypertension is a major risk factor for cardiovascular and cerebrovascular disease, end stage renal disease, type 2 diabetes, and metabolic syndrome. Hypertension has a high global prevalence of about 15% that is estimated to reach as high as 30% by 2025.</offsets><xref rid="b3-ARYA-09-326" ref-type="bibr"><offsets xml_i="6237" xml_f="6238" txt_i="1642" txt_f="1643">3</offsets></xref><offsets xml_i="6245" xml_f="6246" txt_i="1643" txt_f="1644">,</offsets><xref rid="b4-ARYA-09-326" ref-type="bibr"><offsets xml_i="6289" xml_f="6290" txt_i="1644" txt_f="1645">4</offsets></xref><offsets xml_i="6297" xml_f="6497" txt_i="1645" txt_f="1845"> Controlled studies have indicated that each 5 mmHg decrease in diastolic blood pressure (DBP) is associated with 15% and 40% reductions in the risk of cardiovascular disease and stroke, respectively.</offsets><xref rid="b5-ARYA-09-326" ref-type="bibr"><offsets xml_i="6540" xml_f="6541" txt_i="1845" txt_f="1846">5</offsets></xref><offsets xml_i="6548" xml_f="6752" txt_i="1846" txt_f="2050"> In spite the introduction of several classes of anti-hypertensive agents with different mechanisms of action, uncontrolled hypertension resistant to drug therapy still remains a frequent medical problem.</offsets></p><p><offsets xml_i="6759" xml_f="6884" txt_i="2051" txt_f="2176">Pomegranate (Punica granatum L.; Family Punicaceae) is a popular edible fruit with wide applications in traditional medicine.</offsets><xref rid="b6-ARYA-09-326" ref-type="bibr"><offsets xml_i="6927" xml_f="6928" txt_i="2176" txt_f="2177">6</offsets></xref><offsets xml_i="6935" xml_f="6936" txt_i="2177" txt_f="2178">,</offsets><xref rid="b7-ARYA-09-326" ref-type="bibr"><offsets xml_i="6979" xml_f="6980" txt_i="2178" txt_f="2179">7</offsets></xref><offsets xml_i="6987" xml_f="7129" txt_i="2179" txt_f="2321"> Several lines of modern scientific evidence have also indicated the therapeutic efficacy of pomegranate against different types of disorders.</offsets><xref rid="b8-ARYA-09-326" ref-type="bibr"><offsets xml_i="7172" xml_f="7173" txt_i="2321" txt_f="2322">8</offsets></xref><offsets xml_i="7180" xml_f="7181" txt_i="2322" txt_f="2323">-</offsets><xref rid="b11-ARYA-09-326" ref-type="bibr"><offsets xml_i="7225" xml_f="7227" txt_i="2323" txt_f="2325">11</offsets></xref><offsets xml_i="7234" xml_f="7473" txt_i="2325" txt_f="2564"> The pomegranate is characterized by considerable amounts of biologically active phytochemicals including flavonoids (e.g. anthocyanins, catechins, quercetin, and rutin), other types of polyphenols, ellagitannins, and antioxidant vitamins.</offsets><xref rid="b12-ARYA-09-326" ref-type="bibr"><offsets xml_i="7517" xml_f="7519" txt_i="2564" txt_f="2566">12</offsets></xref><offsets xml_i="7526" xml_f="7527" txt_i="2566" txt_f="2567">-</offsets><xref rid="b15-ARYA-09-326" ref-type="bibr"><offsets xml_i="7571" xml_f="7573" txt_i="2567" txt_f="2569">15</offsets></xref><offsets xml_i="7580" xml_f="7772" txt_i="2569" txt_f="2761"> Many of these phytochemicals have been shown to possess antioxidant and anti-inflammatory properties plus additional biological activities such as inhibition of angiotensin converting enzyme.</offsets><xref rid="b16-ARYA-09-326" ref-type="bibr"><offsets xml_i="7816" xml_f="7818" txt_i="2761" txt_f="2763">16</offsets></xref><offsets xml_i="7825" xml_f="7826" txt_i="2763" txt_f="2764">-</offsets><xref rid="b20-ARYA-09-326" ref-type="bibr"><offsets xml_i="7870" xml_f="7872" txt_i="2764" txt_f="2766">20</offsets></xref><offsets xml_i="7879" xml_f="8021" txt_i="2766" txt_f="2908"> All these activities of the pomegranate are potentially beneficial for the treatment of hypertension and improvement of endothelial function.</offsets><xref rid="b11-ARYA-09-326" ref-type="bibr"><offsets xml_i="8065" xml_f="8067" txt_i="2908" txt_f="2910">11</offsets></xref><offsets xml_i="8074" xml_f="8192" txt_i="2910" txt_f="3028"> However, clinical studies investigating the hypotensive and cardioprotective effects of pomegranate have been scarce.</offsets><xref rid="b20-ARYA-09-326" ref-type="bibr"><offsets xml_i="8236" xml_f="8238" txt_i="3028" txt_f="3030">20</offsets></xref><offsets xml_i="8245" xml_f="8246" txt_i="3030" txt_f="3031">-</offsets><xref rid="b26-ARYA-09-326" ref-type="bibr"><offsets xml_i="8290" xml_f="8292" txt_i="3031" txt_f="3033">26</offsets></xref></p><p><offsets xml_i="8306" xml_f="8575" txt_i="3034" txt_f="3297">According to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7), prehypertension is defined as 120 mmHg ≤ systolic blood pressure (SBP) &lt; 140 mmHg 12 and/or 80 mmHg ≤ DBP &lt; 90 mmHg.</offsets><xref rid="b27-ARYA-09-326" ref-type="bibr"><offsets xml_i="8619" xml_f="8621" txt_i="3297" txt_f="3299">27</offsets></xref><offsets xml_i="8628" xml_f="8765" txt_i="3299" txt_f="3436"> Prehypertension is a clinical stage where subjects are at increased risk (2 folds higher) of developing hypertension in the near future.</offsets><xref rid="b28-ARYA-09-326" ref-type="bibr"><offsets xml_i="8809" xml_f="8811" txt_i="3436" txt_f="3438">28</offsets></xref><offsets xml_i="8818" xml_f="9007" txt_i="3438" txt_f="3627"> Emerging findings suggest that interventions at the prehypertension stage can prevent or delay the progression of disease into established hypertension and subsequent detrimental outcomes.</offsets><xref rid="b29-ARYA-09-326" ref-type="bibr"><offsets xml_i="9051" xml_f="9053" txt_i="3627" txt_f="3629">29</offsets></xref><offsets xml_i="9060" xml_f="9222" txt_i="3629" txt_f="3791"> The present trial investigated the acute effects of pomegranate juice (PJ) on blood pressure and endothelial function in subjects with diagnosed prehypertension.</offsets></p></sec><sec sec-type="materials|methods"><title><offsets xml_i="9273" xml_f="9294" txt_i="3793" txt_f="3814">Materials and Methods</offsets></title><p><offsets xml_i="9305" xml_f="9306" txt_i="3815" txt_f="3816">
</offsets><bold><offsets xml_i="9312" xml_f="9320" txt_i="3816" txt_f="3824">Subjects</offsets></bold><offsets xml_i="9327" xml_f="9328" txt_i="3824" txt_f="3825">
</offsets></p><p><offsets xml_i="9335" xml_f="9408" txt_i="3826" txt_f="3899">Thirteen hypertensive men aged 39-68 years were recruited for this trial.</offsets><xref rid="b30-ARYA-09-326" ref-type="bibr"><offsets xml_i="9452" xml_f="9454" txt_i="3899" txt_f="3901">30</offsets></xref><offsets xml_i="9461" xml_f="9649" txt_i="3901" txt_f="4089"> The Ethics Committee at the Shahrekord University of Medical Sciences (Iran) approved the study protocol (code: 92-3-16) and written informed consents were obtained from all participants.</offsets></p><p><offsets xml_i="9656" xml_f="10134" txt_i="4090" txt_f="4559">The inclusion criteria were body mass index (BMI) ≤ 30, and diagnosed hypertension defined as SBP &gt; 120 mmHg and/or DBP &gt; 80 mmHg. Exclusion criteria were type 1 or 2 diabetes, chronic pancreatitis, liver cirrhosis, kidney stones, renal failure, use of non-steroidal anti-inflammatory drugs, use of antioxidant or vitamin supplements, intense physical activity (&gt; 5 h/week), smoking habit, being vegetarian or having any restrictive dietary requirements, and pregnancy.</offsets></p><p><offsets xml_i="10141" xml_f="10142" txt_i="4560" txt_f="4561">
</offsets><bold><offsets xml_i="10148" xml_f="10160" txt_i="4561" txt_f="4573">Study design</offsets></bold><offsets xml_i="10167" xml_f="10168" txt_i="4573" txt_f="4574">
</offsets></p><p><offsets xml_i="10175" xml_f="10731" txt_i="4575" txt_f="5131">The present study was designed as a single-arm clinical trial. The included subjects were assigned to natural PJ (150 ml/day) following a 12-h fast. SBP, DBP, and flow-mediated dilation (FMD), along with serum concentrations of C-reactive protein (CRP), intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin, and interleukin-6 (IL-6) were measured at baseline and 4-6 h after PJ consumption. Participants were asked not to eat or drink anything during the interval between PJ consumption and final measurements.</offsets></p><p><offsets xml_i="10738" xml_f="10739" txt_i="5132" txt_f="5133">
</offsets><bold><offsets xml_i="10745" xml_f="10768" txt_i="5133" txt_f="5156">Total anthocyanin assay</offsets></bold><offsets xml_i="10775" xml_f="10776" txt_i="5156" txt_f="5157">
</offsets></p><p><offsets xml_i="10783" xml_f="11056" txt_i="5158" txt_f="5431">A pH differential method was carried out to determine the total anthocyanin content of PJ. In this method, the difference in the absorbance of sample at pHs 1.0 and 4.5 is proportional to the total anthocyanin content. Details of this method have been published previously.</offsets><xref rid="b24-ARYA-09-326" ref-type="bibr"><offsets xml_i="11100" xml_f="11102" txt_i="5431" txt_f="5433">24</offsets></xref><offsets xml_i="11109" xml_f="11110" txt_i="5433" txt_f="5434">,</offsets><xref rid="b31-ARYA-09-326" ref-type="bibr"><offsets xml_i="11154" xml_f="11156" txt_i="5434" txt_f="5436">31</offsets></xref></p><p><offsets xml_i="11170" xml_f="11171" txt_i="5437" txt_f="5438">
</offsets><bold><offsets xml_i="11177" xml_f="11211" txt_i="5438" txt_f="5472">Anthropometric and BP measurements</offsets></bold><offsets xml_i="11218" xml_f="11219" txt_i="5472" txt_f="5473">
</offsets></p><p><offsets xml_i="11226" xml_f="11326" txt_i="5474" txt_f="5574">Measurement of weight and height was carried out using a standard procedure as described previously.</offsets><xref rid="b24-ARYA-09-326" ref-type="bibr"><offsets xml_i="11370" xml_f="11372" txt_i="5574" txt_f="5576">24</offsets></xref><offsets xml_i="11379" xml_f="11380" txt_i="5576" txt_f="5577">,</offsets><xref rid="b32-ARYA-09-326" ref-type="bibr"><offsets xml_i="11424" xml_f="11426" txt_i="5577" txt_f="5579">32</offsets></xref><offsets xml_i="11433" xml_f="11990" txt_i="5579" txt_f="6136"> Body mass index (BMI) was calculated as weight in kg divided by height in meters squared (m2). BP was measured by a single operator at baseline and 4-6 h after intake of PJ, according to a standard protocol. BP recordings were performed after rest, employing a stethoscope and calibrated sphygmomanometer (Accurtorr 1A; Datascope, Japan). Systolic blood pressure was defined as the appearance of the first sound (Korotkoff phase 1) and diastolic blood pressure was defined as the disappearance of the sound (Korotkoff phase 5) during deflating of the cuff.</offsets><xref rid="b24-ARYA-09-326" ref-type="bibr"><offsets xml_i="12034" xml_f="12036" txt_i="6136" txt_f="6138">24</offsets></xref><offsets xml_i="12043" xml_f="12044" txt_i="6138" txt_f="6139">,</offsets><xref rid="b32-ARYA-09-326" ref-type="bibr"><offsets xml_i="12088" xml_f="12090" txt_i="6139" txt_f="6141">32</offsets></xref></p><p><offsets xml_i="12104" xml_f="12105" txt_i="6142" txt_f="6143">
</offsets><bold><offsets xml_i="12111" xml_f="12126" txt_i="6143" txt_f="6158">FMD measurement</offsets></bold><offsets xml_i="12133" xml_f="12134" txt_i="6158" txt_f="6159">
</offsets></p><p><offsets xml_i="12141" xml_f="12233" txt_i="6160" txt_f="6252">Endothelium-dependent FMD was measured on the right brachial artery as described previously.</offsets><xref rid="b33-ARYA-09-326" ref-type="bibr"><offsets xml_i="12277" xml_f="12279" txt_i="6252" txt_f="6254">33</offsets></xref><offsets xml_i="12286" xml_f="12853" txt_i="6254" txt_f="6821"> All measurements were carried out by a single operator following a 5-min rest and employing a GE vivid 3 ultrasound apparatus (AtCor Medical, Solingen, Germany). A BP cuff was inflated around the forearm to 200 mmHg for 5 min. Images were recorded at baseline (before inflation), 30 s before cuff release, and then every 15 sec after cuff release for 3 min. Arterial diameter was measured at the end of end-diastolic phase, coinciding with R-wave on the electrocardiogram (ECG). Brachial FMD was expressed as the percentage change in arterial diameter from baseline.</offsets><xref rid="b34-ARYA-09-326" ref-type="bibr"><offsets xml_i="12897" xml_f="12899" txt_i="6821" txt_f="6823">34</offsets></xref></p><p><offsets xml_i="12913" xml_f="12914" txt_i="6824" txt_f="6825">
</offsets><bold><offsets xml_i="12920" xml_f="12959" txt_i="6825" txt_f="6864">Blood sampling and biochemical analyses</offsets></bold><offsets xml_i="12966" xml_f="12967" txt_i="6864" txt_f="6865">
</offsets></p><p><offsets xml_i="12974" xml_f="13801" txt_i="6866" txt_f="7693">Twelve-hour fasted blood samples were taken from the left antecubital vein. After being allowed to clot for 2-3 h, serum was isolated by centrifugation at 3500-4000 rpm for 10 min. Serum samples were kept at -80°C prior to biochemical analyses. Biochemical analyses were performed using an automated enzymatic assay (Pars Azmoon, Tehran, Iran) on a Hitachi 902 autoanalyzer (for CRP), or enzyme-linked immunosorbent assay (ELISA) with commercial kits (Boster Biological Technology Ltd., Wuhan, China) (for ICAM-1, VCAM-1, E-selectin, and IL-6). Inter-assay coefficients of variation for ICAM-1, VCAM-1, E-selectin and IL-6 were 4.1-6.4%, 6.1-7.7%, 6.6-8.1%, and 3.1-5.5%, respectively. Intra-assay coefficients of variation for ICAM-1, VCAM-1, E-selectin, and IL-6 were 3.4-5.1%, 2.3-3.7%, 5.2-6.9%, and 2.3-4.9%, respectively.</offsets></p><p><offsets xml_i="13808" xml_f="13809" txt_i="7694" txt_f="7695">
</offsets><bold><offsets xml_i="13815" xml_f="13835" txt_i="7695" txt_f="7715">Statistical analysis</offsets></bold><offsets xml_i="13842" xml_f="13843" txt_i="7715" txt_f="7716">
</offsets></p><p><offsets xml_i="13850" xml_f="14231" txt_i="7717" txt_f="8095">All statistical analyses were performed using SPSS for Windows (version 17; SPSS Inc., Chicago, IL, USA). Data were expressed as mean ± SD. Group comparisons were made using paired t-test (in case of normally distributed data) or Wilcoxon signed-ranks test (in case of non-normally distributed data). A two-sided P-value of &lt; 0.05 was considered to be statistically significant.</offsets></p></sec><sec sec-type="result"><title><offsets xml_i="14271" xml_f="14278" txt_i="8097" txt_f="8104">Results</offsets></title><p><offsets xml_i="14289" xml_f="14596" txt_i="8105" txt_f="8412">This trial was a comprised of 13 hypertensive male adolescents with a mean age, weight, and BMI of 55.92 ± 7.92 yrs, 80.42 ± 11.01 kg, and 27.34 ± 3.82 kg/m2, respectively. All 13 subjects completed the study. Total anthocyanin content of PJ was determined to be 5.8 mg per 100 ml of the administered juice.</offsets></p><p><offsets xml_i="14603" xml_f="15223" txt_i="8413" txt_f="9033">Comparison of pre- vs. post-trial values revealed a significant reduction in both SBP (P = 0.013) and DBP (P = 0.010), amounting to an approximate reduction by 7% and 6%, respectively. However, percentage changes in FMD (20%) was not found to be statistically significant (P = 0.172). In the same manner, there was no significant difference in the circulating concentrations of inflammatory biomarkers namely hsCRP (P = 0.263), ICAM-1 (P = 0.248), VCAM-1 (P = 0.657), E-selectin (P = 0.182), and IL-6 (P = 0.763) following consumption of PJ. Baseline and post-trial values for the evaluated parameters are summarized in </offsets><xref ref-type="table" rid="t1-ARYA-09-326"><offsets xml_i="15267" xml_f="15274" txt_i="9033" txt_f="9040">table 1</offsets></xref><offsets xml_i="15281" xml_f="15282" txt_i="9040" txt_f="9041">.</offsets></p></sec><sec sec-type="discussion"><title><offsets xml_i="15326" xml_f="15336" txt_i="9043" txt_f="9053">Discussion</offsets></title><p><offsets xml_i="15347" xml_f="15710" txt_i="9054" txt_f="9417">The present pilot trial is one of the few clinical evidences on the acute hypotensive and vascular effects of PJ. The results indicated amelioration of both SBP and DBP following consumption of a single dose of PJ. In a previous study, Aviram and Dornfeld investigated the effects of 2-week supplementation with PJ (50 ml/day) on the SBP of hypertensive patients.</offsets><xref rid="b20-ARYA-09-326" ref-type="bibr"><offsets xml_i="15754" xml_f="15756" txt_i="9417" txt_f="9419">20</offsets></xref><offsets xml_i="15763" xml_f="15950" txt_i="9419" txt_f="9606"> The findings revealed a significant decrease in SBP amounting to 5%. In the same study, a 36% decrement in the activity of serum angiotensin converting enzyme (ACE) was reported from PJ.</offsets><xref rid="b20-ARYA-09-326" ref-type="bibr"><offsets xml_i="15994" xml_f="15996" txt_i="9606" txt_f="9608">20</offsets></xref></p><p><offsets xml_i="16010" xml_f="16434" txt_i="9609" txt_f="10033">The same group also investigated the effect of chronic supplementation with PJ (50 ml/day) in patients with carotid artery stenosis. Their results indicated a significant reduction in SBP, but not DBP, starting from 1 month after starting supplementation and generally increasing up to month 12 (equivalent to 12% decrement). However, no further reduction was observed when supplementation was continued for another 2 years.</offsets><xref rid="b21-ARYA-09-326" ref-type="bibr"><offsets xml_i="16478" xml_f="16480" txt_i="10033" txt_f="10035">21</offsets></xref><offsets xml_i="16487" xml_f="16654" txt_i="10035" txt_f="10202"> Another study conducted by Lynn et al. indicated a significant reduction in both SBP and DBP following consumption of PJ (330 ml/day) by healthy subjects for 4 weeks.</offsets><xref rid="b22-ARYA-09-326" ref-type="bibr"><offsets xml_i="16698" xml_f="16700" txt_i="10202" txt_f="10204">22</offsets></xref><offsets xml_i="16707" xml_f="16946" txt_i="10204" txt_f="10443"> Mathew et al. reported that consumption of pomegranate extract, either during or 15 min before a high-fat meal, can effectively prevent postprandial SBP rise at 2 and 4 h postprandial. Nevertheless, no significant effect was found on DBP.</offsets><xref rid="b23-ARYA-09-326" ref-type="bibr"><offsets xml_i="16990" xml_f="16992" txt_i="10443" txt_f="10445">23</offsets></xref><offsets xml_i="16999" xml_f="17322" txt_i="10445" txt_f="10768"> In a recent trial conducted by our group, the effects of a 2-week intake of PJ (from the same source as that used in the present study) were evaluated on BP of hypertensive subjects. Our results implied a significant reduction of both SBP (5%) and DBP (4.5%) compared to the control group who consumed water instead of PJ.</offsets><xref rid="b24-ARYA-09-326" ref-type="bibr"><offsets xml_i="17366" xml_f="17368" txt_i="10768" txt_f="10770">24</offsets></xref><offsets xml_i="17375" xml_f="17717" txt_i="10770" txt_f="11112"> Although most of the findings by previous trials infer the hypotensive impact of PJ consumption, there are some contrasting findings that are worth attention. Kelishadi et al. investigated the acute (4 h) and chronic (1 month) effects of PJ (240 ml/day) on BP of adolescents with metabolic syndrome and could not find any significant effect.</offsets><xref rid="b25-ARYA-09-326" ref-type="bibr"><offsets xml_i="17761" xml_f="17763" txt_i="11112" txt_f="11114">25</offsets></xref><offsets xml_i="17770" xml_f="17967" txt_i="11114" txt_f="11311"> In another trial, administration of PJ (240 ml/day) for 3 months was not found to significantly affect SBP or DBP in patients with stable coronary heart disease (CHD), as reported by Sumner et al.</offsets><xref rid="b26-ARYA-09-326" ref-type="bibr"><offsets xml_i="18011" xml_f="18013" txt_i="11311" txt_f="11313">26</offsets></xref><offsets xml_i="18020" xml_f="18435" txt_i="11313" txt_f="11728"> These negative findings might be attributed to the difference in the inclusion criteria applied by these two latter trials. It appears that hypotensive effects of PJ are more likely to be elicited in hypertensive patients, rather than patients with established CHD or metabolic syndrome. Moreover, the overall findings of the trials conducted so far weigh in favor of the beneficial effect of PJ consumption on BP.</offsets></p><p><offsets xml_i="18442" xml_f="18663" txt_i="11729" txt_f="11950">The hypotensive properties of PJ could be ascribed to the promising antioxidant properties of phytochemicals present in this complex juice. Oxidative stress is known to play a key role in the pathogenesis of hypertension.</offsets><xref rid="b35-ARYA-09-326" ref-type="bibr"><offsets xml_i="18707" xml_f="18709" txt_i="11950" txt_f="11952">35</offsets></xref><offsets xml_i="18716" xml_f="18811" txt_i="11952" txt_f="12047"> Increased levels of oxidants have been shown in different experimental models of hypertension.</offsets><xref rid="b36-ARYA-09-326" ref-type="bibr"><offsets xml_i="18855" xml_f="18857" txt_i="12047" txt_f="12049">36</offsets></xref><offsets xml_i="18864" xml_f="18865" txt_i="12049" txt_f="12050">-</offsets><xref rid="b39-ARYA-09-326" ref-type="bibr"><offsets xml_i="18909" xml_f="18911" txt_i="12050" txt_f="12052">39</offsets></xref><offsets xml_i="18918" xml_f="19360" txt_i="12052" txt_f="12494"> Detrimental effects of oxidative stress are mainly due to the interaction of reactive oxygen species (ROS) (in particular superoxide anion) with vital cellular components, lipids, and proteins, which leads to endothelial dysfunction and vascular resistance. In addition, ROS interfere with the production and vasodilatory actions of endothelium-derived nitric oxide (NO) via attenuating NO synthase (NOS) activity and enhancing NO breakdown.</offsets><xref rid="b40-ARYA-09-326" ref-type="bibr"><offsets xml_i="19404" xml_f="19406" txt_i="12494" txt_f="12496">40</offsets></xref><offsets xml_i="19413" xml_f="19414" txt_i="12496" txt_f="12497">,</offsets><xref rid="b41-ARYA-09-326" ref-type="bibr"><offsets xml_i="19458" xml_f="19460" txt_i="12497" txt_f="12499">41</offsets></xref><offsets xml_i="19467" xml_f="19635" txt_i="12499" txt_f="12667"> Epidemiological evidence has indicated that diets rich in natural antioxidants are associated with a reduced risk of developing hypertension and cardiovascular events.</offsets><xref rid="b42-ARYA-09-326" ref-type="bibr"><offsets xml_i="19679" xml_f="19681" txt_i="12667" txt_f="12669">42</offsets></xref><offsets xml_i="19688" xml_f="19689" txt_i="12669" txt_f="12670">,</offsets><xref rid="b43-ARYA-09-326" ref-type="bibr"><offsets xml_i="19733" xml_f="19735" txt_i="12670" txt_f="12672">43</offsets></xref><offsets xml_i="19742" xml_f="20083" txt_i="12672" txt_f="13013"> A plethora of studies have confirmed the considerable antioxidant and radical scavenging effects of PJ, which are mainly due to the anthocyanins and hydrolysable tannins present in the fruit. Interestingly, it has been suggested that some 50% of the total antioxidant activity of PJ is exerted by a specific ellagitannin, named punicalagin.</offsets><xref rid="b16-ARYA-09-326" ref-type="bibr"><offsets xml_i="20127" xml_f="20129" txt_i="13013" txt_f="13015">16</offsets></xref><offsets xml_i="20136" xml_f="20242" txt_i="13015" txt_f="13121"> Intestinal hydrolysis of punicalagin yields ellagic acid; the latter being a strong antioxidant compound.</offsets><xref rid="b44-ARYA-09-326" ref-type="bibr"><offsets xml_i="20286" xml_f="20288" txt_i="13121" txt_f="13123">44</offsets></xref></p><p><offsets xml_i="20302" xml_f="20532" txt_i="13124" txt_f="13354">Apart from antioxidant properties, PJ may lower BP through a direct interaction with ACE. As referred above, a significant reduction in the activity of serum ACE has been observed in hypertensive patients following PJ consumption.</offsets><xref rid="b20-ARYA-09-326" ref-type="bibr"><offsets xml_i="20576" xml_f="20578" txt_i="13354" txt_f="13356">20</offsets></xref><offsets xml_i="20585" xml_f="20920" txt_i="13356" txt_f="13691"> Besides, in an animal study by Mohan et al. PJ administration attenuated angiotensin II-induced hypertension in diabetic rats, and also blocked the effects of different catecholamines on arterial BP and vasoreactivity. Furthermore, chronic administration of PJ counterbalanced the increased ACE activity in diabetic hypertensive rats.</offsets><xref rid="b45-ARYA-09-326" ref-type="bibr"><offsets xml_i="20964" xml_f="20966" txt_i="13691" txt_f="13693">45</offsets></xref><offsets xml_i="20973" xml_f="21178" txt_i="13693" txt_f="13898"> In spite of these positive reports, the ACE inhibitory effect of PJ needs to be further explored as Lynn et al. failed to report any change in serum ACE concentration following PJ consumption for 4 weeks.</offsets><xref rid="b22-ARYA-09-326" ref-type="bibr"><offsets xml_i="21222" xml_f="21224" txt_i="13898" txt_f="13900">22</offsets></xref></p><p><offsets xml_i="21238" xml_f="21506" txt_i="13901" txt_f="14169">Another primary outcome measure that was evaluated by the present trial was changes in endothelium-dependent flow-mediated dilation. Our results did not indicate any improvement in FMD and this is in agreement with our recent report on the effects of 2-week PJ intake.</offsets><xref rid="b24-ARYA-09-326" ref-type="bibr"><offsets xml_i="21550" xml_f="21552" txt_i="14169" txt_f="14171">24</offsets></xref><offsets xml_i="21559" xml_f="21845" txt_i="14171" txt_f="14457"> However, findings from another trial indicated significant improvement in both endothelium-dependent and -independent (nitroglycerin-induced) dilation after 4 h of PJ consumption. In addition, this increased vasodilation was persisted until the end of supplementation period (1 month).</offsets><xref rid="b25-ARYA-09-326" ref-type="bibr"><offsets xml_i="21889" xml_f="21891" txt_i="14457" txt_f="14459">25</offsets></xref><offsets xml_i="21898" xml_f="22591" txt_i="14459" txt_f="15152"> In the present study, biomarkers of endothelial function, namely ICAM-1, VCAM-1, and E-selectin, remained statistically unaltered compared to baseline levels. It should be noticed that alterations in the circulating levels of these biomarkers is more likely to be exerted by chronic, rather than single dose, consumption of PJ and needs a longer term evaluation to allow the turnover of previously released proteins and observation of possible changes in the expression and subsequent release of these markers due to PJ consumption. This notion is corroborated by our previous study which showed a decreasing trend in serum levels of the aforementioned biomarkers following consumption of PJ.</offsets><xref rid="b24-ARYA-09-326" ref-type="bibr"><offsets xml_i="22635" xml_f="22637" txt_i="15152" txt_f="15154">24</offsets></xref></p><p><offsets xml_i="22651" xml_f="23274" txt_i="15155" txt_f="15778">The present study has certain limitations that need to be acknowledged. This study did not include a control group. Therefore, our findings might have been confounded by bias. In addition, the present trial was conducted in pilot scale and with a small population size. This small size could potentially account for lack of detecting significant difference despite the increasing trend in FMD and decreasing trends in serum CRP, ICAM-1, VCAM-1, and E-selectin levels. With respect to these limitations, findings of the present trial may not be generalizable to the general population and should be interpreted with caution.</offsets></p><p><offsets xml_i="23281" xml_f="23708" txt_i="15779" txt_f="16206">In conclusion, the key finding to emerge from the present study is the acute hypotensive effect of PJ in hypertensive patients. While this trial is not a substitution for well-designed randomized controlled trials, it generates a hypothesis and motivates further research on this topic. Future large-scale investigations are indeed warranted in order to obtain a mechanistic understanding on this observed hypotensive activity.</offsets></p></sec></body><back><ack><title>Acknowledgments</title><p>This study was conducted with financial support that was provided by the Shahrekord University of Medical Sciences, Shahrekord, Iran.</p></ack><fn-group><fn><p>
<bold>Conflicts of Interest</bold>
</p><p>Authors have no conflict of interests.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="b1-ARYA-09-326"><label>1</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kochanek</surname><given-names>KD</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Murphy</surname><given-names>SL</given-names></name><name><surname>Minino</surname><given-names>AM</given-names></name><name><surname>Kung</surname><given-names>HC</given-names></name></person-group>
<article-title> Deaths: Final Data for 2009.</article-title>
<source>National Vital Statistics Reports</source>
<year>2011</year>
<volume>60</volume>
<issue>3</issue>
<fpage>1</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="pmid">22670489</pub-id></element-citation></ref><ref id="b2-ARYA-09-326"><label>2</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Whitworth</surname><given-names>JA</given-names></name></person-group>
<article-title> 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension.</article-title>
<source>J Hypertens</source>
<year>2003</year>
<volume>21</volume>
<issue>11</issue>
<fpage>1983</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="pmid">14597836</pub-id></element-citation></ref><ref id="b3-ARYA-09-326"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kearney</surname><given-names>PM</given-names></name><name><surname>Whelton</surname><given-names>M</given-names></name><name><surname>Reynolds</surname><given-names>K</given-names></name><name><surname>Muntner</surname><given-names>P</given-names></name><name><surname>Whelton</surname><given-names>PK</given-names></name><name><surname>He</surname><given-names>J</given-names></name></person-group>
<article-title> Global burden of hypertension: analysis of worldwide data.</article-title>
<source>Lancet</source>
<year>2005</year>
<volume>365</volume>
<issue>9455</issue>
<fpage>217</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">15652604</pub-id></element-citation></ref><ref id="b4-ARYA-09-326"><label>4</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hajjar</surname><given-names>I</given-names></name><name><surname>Kotchen</surname><given-names>JM</given-names></name><name><surname>Kotchen</surname><given-names>TA</given-names></name></person-group>
<article-title> Hypertension: trends in prevalence, incidence, and control.</article-title>
<source>Annu Rev Public Health</source>
<year>2006</year>
<volume>27</volume>
<fpage>465</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="pmid">16533126</pub-id></element-citation></ref><ref id="b5-ARYA-09-326"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fazizi</surname><given-names>F</given-names></name><name><surname>Esmaillzadeh</surname><given-names>A</given-names></name><name><surname>Mirmiran</surname><given-names>FP</given-names></name></person-group>
<article-title> Obesity and cardiovascular disease risk factors in Tehran adults: a population-based study.</article-title>
<source>East Mediterr Health J</source>
<year>2004</year>
<volume>10</volume>
<issue>6</issue>
<fpage>887</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="pmid">16335777</pub-id></element-citation></ref><ref id="b6-ARYA-09-326"><label>6</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lansky</surname><given-names>EP</given-names></name><name><surname>Newman</surname><given-names>RA</given-names></name></person-group>
<article-title> Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer.</article-title>
<source>J Ethnopharmacol</source>
<year>2007</year>
<volume>109</volume>
<issue>2</issue>
<fpage>177</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="pmid">17157465</pub-id></element-citation></ref><ref id="b7-ARYA-09-326"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amruthesh</surname><given-names>S</given-names></name></person-group>
<article-title> Dentistry and ayurveda v-an evidence based approach.</article-title>
<source>International Journal of Clinical Dental Science</source>
<year>2011</year>
<volume>2</volume>
<issue>1</issue>
<fpage>3</fpage>
<lpage>9</lpage>
</element-citation></ref><ref id="b8-ARYA-09-326"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ismail</surname><given-names>T</given-names></name><name><surname>Sestili</surname><given-names>P</given-names></name><name><surname>Akhtar</surname><given-names>S</given-names></name></person-group>
<article-title> Pomegranate peel and fruit extracts: a review of potential anti-inflammatory and anti-infective effects.</article-title>
<source>J Ethnopharmacol</source>
<year>2012</year>
<volume>143</volume>
<issue>2</issue>
<fpage>397</fpage>
<lpage>405</lpage>
<pub-id pub-id-type="pmid">22820239</pub-id></element-citation></ref><ref id="b9-ARYA-09-326"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johanningsmeier</surname><given-names>SD</given-names></name><name><surname>Harris</surname><given-names>GK</given-names></name></person-group>
<article-title> Pomegranate as a functional food and nutraceutical source.</article-title>
<source>Annu Rev Food Sci Technol</source>
<year>2011</year>
<volume>2</volume>
<fpage>181</fpage>
<lpage>201</lpage>
<pub-id pub-id-type="pmid">22129380</pub-id></element-citation></ref><ref id="b10-ARYA-09-326"><label>10</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haber</surname><given-names>SL</given-names></name><name><surname>Joy</surname><given-names>JK</given-names></name><name><surname>Largent</surname><given-names>R</given-names></name></person-group>
<article-title> Antioxidant and antiatherogenic effects of pomegranate.</article-title>
<source>Am J Health Syst Pharm</source>
<year>2011</year>
<volume>68</volume>
<issue>14</issue>
<fpage>1302</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">21719590</pub-id></element-citation></ref><ref id="b11-ARYA-09-326"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stowe</surname><given-names>CB</given-names></name></person-group>
<article-title> The effects of pomegranate juice consumption on blood pressure and cardiovascular health.</article-title>
<source>Complement Ther Clin Pract</source>
<year>2011</year>
<volume>17</volume>
<issue>2</issue>
<fpage>113</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">21457902</pub-id></element-citation></ref><ref id="b12-ARYA-09-326"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jurenka</surname><given-names>JS</given-names></name></person-group>
<article-title> Therapeutic applications of pomegranate (Punica granatum L.): a review.</article-title>
<source>Altern Med Rev</source>
<year>2008</year>
<volume>13</volume>
<issue>2</issue>
<fpage>128</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="pmid">18590349</pub-id></element-citation></ref><ref id="b13-ARYA-09-326"><label>13</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>S</given-names></name></person-group>
<article-title> Evaluation of antioxidant properties of pomegranate peel extract in comparison with pomegranate pulp extract.</article-title>
<source>Food Chemistry</source>
<year>2006</year>
<volume>96</volume>
<issue>2</issue>
<fpage>254</fpage>
<lpage>60</lpage>
</element-citation></ref><ref id="b14-ARYA-09-326"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tezcan</surname><given-names>F</given-names></name><name><surname>Gültekin-Ozgüven</surname><given-names>M</given-names></name><name><surname>Diken</surname><given-names>T</given-names></name><name><surname>Ozcelik</surname><given-names>B</given-names></name><name><surname>Erim</surname><given-names>FB</given-names></name></person-group>
<article-title> Antioxidant activity and total phenolic, organic acid and sugar content in commercial pomegranate juices.</article-title>
<source>Food Chemistry</source>
<year>2009</year>
<volume>115</volume>
<issue>3</issue>
<fpage>873</fpage>
<lpage>7</lpage>
</element-citation></ref><ref id="b15-ARYA-09-326"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Afaq</surname><given-names>F</given-names></name><name><surname>Saleem</surname><given-names>M</given-names></name><name><surname>Krueger</surname><given-names>CG</given-names></name><name><surname>Reed</surname><given-names>JD</given-names></name><name><surname>Mukhtar</surname><given-names>H</given-names></name></person-group>
<article-title> Anthocyanin- and hydrolyzable tannin-rich pomegranate fruit extract modulates MAPK and NF-kappaB pathways and inhibits skin tumorigenesis in CD-1 mice.</article-title>
<source>Int J Cancer</source>
<year>2005</year>
<volume>113</volume>
<issue>3</issue>
<fpage>423</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="pmid">15455341</pub-id></element-citation></ref><ref id="b16-ARYA-09-326"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gil</surname><given-names>MI</given-names></name><name><surname>Tomas-Barberan</surname><given-names>FA</given-names></name><name><surname>Hess-Pierce</surname><given-names>B</given-names></name><name><surname>Holcroft</surname><given-names>DM</given-names></name><name><surname>Kader</surname><given-names>AA</given-names></name></person-group>
<article-title> Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing.</article-title>
<source>J Agric Food Chem</source>
<year>2000</year>
<volume>48</volume>
<issue>10</issue>
<fpage>4581</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">11052704</pub-id></element-citation></ref><ref id="b17-ARYA-09-326"><label>17</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shukla</surname><given-names>M</given-names></name><name><surname>Gupta</surname><given-names>K</given-names></name><name><surname>Rasheed</surname><given-names>Z</given-names></name><name><surname>Khan</surname><given-names>KA</given-names></name><name><surname>Haqqi</surname><given-names>TM</given-names></name></person-group>
<article-title> Bioavailable constituents/metabolites of pomegranate (Punica granatum L) preferentially inhibit COX2 activity ex vivo and IL-1beta-induced PGE2 production in human chondrocytes in vitro.</article-title>
<source>J Inflamm (Lond)</source>
<year>2008</year>
<volume>5</volume>
<fpage>9</fpage>
<pub-id pub-id-type="pmid">18554383</pub-id></element-citation></ref><ref id="b18-ARYA-09-326"><label>18</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Akpinar-Bayizit</surname><given-names>A</given-names></name><name><surname>Ozcan</surname><given-names>T</given-names></name><name><surname>Yilmaz-Ersan</surname><given-names>L</given-names></name></person-group>
<article-title> The Therapeutic Potential of Pomegranate and Its Products for Prevention of Cancer.</article-title>
<person-group person-group-type="editor"><name><surname>Georgakilas</surname><given-names>A</given-names></name></person-group>
<source>Cancer Prevention-From Mechanisms to Translational Benefits.</source>
<publisher-loc>Winchester, UK</publisher-loc>
<publisher-name>INTECH</publisher-name>
<year>2012</year>
</element-citation></ref><ref id="b19-ARYA-09-326"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chong</surname><given-names>MF</given-names></name><name><surname>Macdonald</surname><given-names>R</given-names></name><name><surname>Lovegrove</surname><given-names>JA</given-names></name></person-group>
<article-title> Fruit polyphenols and CVD risk: a review of human intervention studies.</article-title>
<source>Br J Nutr</source>
<year>2010</year>
<volume>104</volume>
<issue>Suppl 3</issue>
<fpage>S28</fpage>
<lpage>S39</lpage>
<pub-id pub-id-type="pmid">20955648</pub-id></element-citation></ref><ref id="b20-ARYA-09-326"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aviram</surname><given-names>M</given-names></name><name><surname>Dornfeld</surname><given-names>L</given-names></name></person-group>
<article-title> Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure.</article-title>
<source>Atherosclerosis</source>
<year>2001</year>
<volume>158</volume>
<issue>1</issue>
<fpage>195</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">11500191</pub-id></element-citation></ref><ref id="b21-ARYA-09-326"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aviram</surname><given-names>M</given-names></name><name><surname>Rosenblat</surname><given-names>M</given-names></name><name><surname>Gaitini</surname><given-names>D</given-names></name><name><surname>Nitecki</surname><given-names>S</given-names></name><name><surname>Hoffman</surname><given-names>A</given-names></name><name><surname>Dornfeld</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title> Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation.</article-title>
<source>Clin Nutr</source>
<year>2004</year>
<volume>23</volume>
<issue>3</issue>
<fpage>423</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="pmid">15158307</pub-id></element-citation></ref><ref id="b22-ARYA-09-326"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lynn</surname><given-names>A</given-names></name><name><surname>Hamadeh</surname><given-names>H</given-names></name><name><surname>Leung</surname><given-names>WC</given-names></name><name><surname>Russell</surname><given-names>JM</given-names></name><name><surname>Barker</surname><given-names>ME</given-names></name></person-group>
<article-title> Effects of pomegranate juice supplementation on pulse wave velocity and blood pressure in healthy young and middle-aged men and women.</article-title>
<source>Plant Foods Hum Nutr</source>
<year>2012</year>
<volume>67</volume>
<issue>3</issue>
<fpage>309</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">22648092</pub-id></element-citation></ref><ref id="b23-ARYA-09-326"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mathew</surname><given-names>AS</given-names></name><name><surname>Capel-Williams</surname><given-names>GM</given-names></name><name><surname>Berry</surname><given-names>SE</given-names></name><name><surname>Hall</surname><given-names>WL</given-names></name></person-group>
<article-title> Acute effects of pomegranate extract on postprandial lipaemia, vascular function and blood pressure.</article-title>
<source>Plant Foods Hum Nutr</source>
<year>2012</year>
<volume>67</volume>
<issue>4</issue>
<fpage>351</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">23093401</pub-id></element-citation></ref><ref id="b24-ARYA-09-326"><label>24</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Asgary</surname><given-names>S</given-names></name><name><surname>Sahebkar</surname><given-names>A</given-names></name><name><surname>Afshani</surname><given-names>MR</given-names></name><name><surname>Keshvari</surname><given-names>M</given-names></name><name><surname>Haghjooyjavanmard</surname><given-names>S</given-names></name><name><surname>Rafieian-Kopaei</surname><given-names>M</given-names></name></person-group>
<article-title> Clinical Evaluation of Blood Pressure Lowering, Endothelial Function Improving, Hypolipidemic and Anti-Inflammatory Effects of Pomegranate Juice in Hypertensive Subjects.</article-title>
<source>Phytother Res</source>
<year>2013</year>
</element-citation></ref><ref id="b25-ARYA-09-326"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kelishadi</surname><given-names>R</given-names></name><name><surname>Gidding</surname><given-names>SS</given-names></name><name><surname>Hashemi</surname><given-names>M</given-names></name><name><surname>Hashemipour</surname><given-names>M</given-names></name><name><surname>Zakerameli</surname><given-names>A</given-names></name><name><surname>Poursafa</surname><given-names>P</given-names></name></person-group>
<article-title> Acute and long term effects of grape and pomegranate juice consumption on endothelial dysfunction in pediatric metabolic syndrome.</article-title>
<source>J Res Med Sci</source>
<year>2011</year>
<volume>16</volume>
<issue>3</issue>
<fpage>245</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="pmid">22091240</pub-id></element-citation></ref><ref id="b26-ARYA-09-326"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sumner</surname><given-names>MD</given-names></name><name><surname>Elliott-Eller</surname><given-names>M</given-names></name><name><surname>Weidner</surname><given-names>G</given-names></name><name><surname>Daubenmier</surname><given-names>JJ</given-names></name><name><surname>Chew</surname><given-names>MH</given-names></name><name><surname>Marlin</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title> Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease.</article-title>
<source>Am J Cardiol</source>
<year>2005</year>
<volume>96</volume>
<issue>6</issue>
<fpage>810</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="pmid">16169367</pub-id></element-citation></ref><ref id="b27-ARYA-09-326"><label>27</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chobanian</surname><given-names>AV</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><name><surname>Black</surname><given-names>HR</given-names></name><name><surname>Cushman</surname><given-names>WC</given-names></name><name><surname>Green</surname><given-names>LA</given-names></name><name><surname>Izzo</surname><given-names>JL</given-names></name><etal></etal></person-group>
<article-title> Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.</article-title>
<source>Hypertension</source>
<year>2003</year>
<volume>42</volume>
<issue>6</issue>
<fpage>1206</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">14656957</pub-id></element-citation></ref><ref id="b28-ARYA-09-326"><label>28</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vasan</surname><given-names>RS</given-names></name><name><surname>Larson</surname><given-names>MG</given-names></name><name><surname>Leip</surname><given-names>EP</given-names></name><name><surname>Kannel</surname><given-names>WB</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name></person-group>
<article-title> Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study.</article-title>
<source>Lancet</source>
<year>2001</year>
<volume>358</volume>
<issue>9294</issue>
<fpage>1682</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">11728544</pub-id></element-citation></ref><ref id="b29-ARYA-09-326"><label>29</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Savica</surname><given-names>V</given-names></name><name><surname>Bellinghieri</surname><given-names>G</given-names></name><name><surname>Kopple</surname><given-names>JD</given-names></name></person-group>
<article-title> The effect of nutrition on blood pressure.</article-title>
<source>Annu Rev Nutr</source>
<year>2010</year>
<volume>30</volume>
<fpage>365</fpage>
<lpage>401</lpage>
<pub-id pub-id-type="pmid">20645853</pub-id></element-citation></ref><ref id="b30-ARYA-09-326"><label>30</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amr</surname><given-names>M</given-names></name><name><surname>El-Mogy</surname><given-names>A</given-names></name><name><surname>Shams</surname><given-names>T</given-names></name><name><surname>Vieira</surname><given-names>K</given-names></name><name><surname>Lakhan</surname><given-names>SE</given-names></name></person-group>
<article-title> Efficacy of vitamin C as an adjunct to fluoxetine therapy in pediatric major depressive disorder: a randomized, double-blind, placebo-controlled pilot study.</article-title>
<source>Nutr J</source>
<year>2013</year>
<volume>12</volume>
<fpage>31</fpage>
<pub-id pub-id-type="pmid">23510529</pub-id></element-citation></ref><ref id="b31-ARYA-09-326"><label>31</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Durst</surname><given-names>RW</given-names></name><name><surname>Wrolstad</surname><given-names>RE</given-names></name></person-group>
<article-title> Determination of total monomeric anthocyanin pigment content of fruit juices, beverages, natural colorants, and wines by the pH differential method: collaborative study.</article-title>
<source>J AOAC Int</source>
<year>2005</year>
<volume>88</volume>
<issue>5</issue>
<fpage>1269</fpage>
<lpage>78</lpage>
<pub-id pub-id-type="pmid">16385975</pub-id></element-citation></ref><ref id="b32-ARYA-09-326"><label>32</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moohebati</surname><given-names>M</given-names></name><name><surname>Bidmeshgi</surname><given-names>S</given-names></name><name><surname>Azarpazhooh</surname><given-names>MR</given-names></name><name><surname>Daloee</surname><given-names>MH</given-names></name><name><surname>Ghayour-Mobarhan</surname><given-names>M</given-names></name><name><surname>Tavallaie</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title> Simvastatin treatment reduces heat shock protein 60, 65, and 70 antibody titers in dyslipidemic patients: A randomized, double-blind, placebo-controlled, cross-over trial.</article-title>
<source>Clin Biochem</source>
<year>2011</year>
<volume>44</volume>
<issue>2-3</issue>
<fpage>192</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">20875810</pub-id></element-citation></ref><ref id="b33-ARYA-09-326"><label>33</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Corretti</surname><given-names>MC</given-names></name><name><surname>Anderson</surname><given-names>TJ</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Celermajer</surname><given-names>D</given-names></name><name><surname>Charbonneau</surname><given-names>F</given-names></name><name><surname>Creager</surname><given-names>MA</given-names></name><etal></etal></person-group>
<article-title> Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force.</article-title>
<source>J Am Coll Cardiol</source>
<year>2002</year>
<volume>39</volume>
<issue>2</issue>
<fpage>257</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="pmid">11788217</pub-id></element-citation></ref><ref id="b34-ARYA-09-326"><label>34</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dickinson</surname><given-names>KM</given-names></name><name><surname>Keogh</surname><given-names>JB</given-names></name><name><surname>Clifton</surname><given-names>PM</given-names></name></person-group>
<article-title> Effects of a low-salt diet on flow-mediated dilatation in humans.</article-title>
<source>Am J Clin Nutr</source>
<year>2009</year>
<volume>89</volume>
<issue>2</issue>
<fpage>485</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="pmid">19106240</pub-id></element-citation></ref><ref id="b35-ARYA-09-326"><label>35</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Griendling</surname><given-names>KK</given-names></name><name><surname>FitzGerald</surname><given-names>GA</given-names></name></person-group>
<article-title> Oxidative stress and cardiovascular injury: Part II: animal and human studies.</article-title>
<source>Circulation</source>
<year>2003</year>
<volume>108</volume>
<issue>17</issue>
<fpage>2034</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="pmid">14581381</pub-id></element-citation></ref><ref id="b36-ARYA-09-326"><label>36</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Friedman</surname><given-names>J</given-names></name><name><surname>Peleg</surname><given-names>E</given-names></name><name><surname>Kagan</surname><given-names>T</given-names></name><name><surname>Shnizer</surname><given-names>S</given-names></name><name><surname>Rosenthal</surname><given-names>T</given-names></name></person-group>
<article-title> Oxidative stress in hypertensive,diabetic, and diabetic hypertensive rats.</article-title>
<source>Am J Hypertens</source>
<year>2003</year>
<volume>16</volume>
<issue>12</issue>
<fpage>1049</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">14643580</pub-id></element-citation></ref><ref id="b37-ARYA-09-326"><label>37</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Trolliet</surname><given-names>MR</given-names></name><name><surname>Rudd</surname><given-names>MA</given-names></name><name><surname>Loscalzo</surname><given-names>J</given-names></name></person-group>
<article-title> Oxidative stress and renal dysfunction in salt-sensitive hypertension.</article-title>
<source>Kidney Blood Press Res</source>
<year>2001</year>
<volume>24</volume>
<issue>2</issue>
<fpage>116</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">11435744</pub-id></element-citation></ref><ref id="b38-ARYA-09-326"><label>38</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lerman</surname><given-names>LO</given-names></name><name><surname>Nath</surname><given-names>KA</given-names></name><name><surname>Rodriguez-Porcel</surname><given-names>M</given-names></name><name><surname>Krier</surname><given-names>JD</given-names></name><name><surname>Schwartz</surname><given-names>RS</given-names></name><name><surname>Napoli</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title> Increased oxidative stress in experimental renovascular hypertension.</article-title>
<source>Hypertension</source>
<year>2001</year>
<volume>37</volume>
<issue>2 Pt 2</issue>
<fpage>541</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">11230332</pub-id></element-citation></ref><ref id="b39-ARYA-09-326"><label>39</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dobrian</surname><given-names>AD</given-names></name><name><surname>Davies</surname><given-names>MJ</given-names></name><name><surname>Schriver</surname><given-names>SD</given-names></name><name><surname>Lauterio</surname><given-names>TJ</given-names></name><name><surname>Prewitt</surname><given-names>RL</given-names></name></person-group>
<article-title> Oxidative stress in a rat model of obesity-induced hypertension.</article-title>
<source>Hypertension</source>
<year>2001</year>
<volume>37</volume>
<issue>2 Pt 2</issue>
<fpage>554</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">11230334</pub-id></element-citation></ref><ref id="b40-ARYA-09-326"><label>40</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Laursen</surname><given-names>JB</given-names></name><name><surname>Somers</surname><given-names>M</given-names></name><name><surname>Kurz</surname><given-names>S</given-names></name><name><surname>McCann</surname><given-names>L</given-names></name><name><surname>Warnholtz</surname><given-names>A</given-names></name><name><surname>Freeman</surname><given-names>BA</given-names></name><etal></etal></person-group>
<article-title> Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin.</article-title>
<source>Circulation</source>
<year>2001</year>
<volume>103</volume>
<issue>9</issue>
<fpage>1282</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">11238274</pub-id></element-citation></ref><ref id="b41-ARYA-09-326"><label>41</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beckman</surname><given-names>JS</given-names></name><name><surname>Koppenol</surname><given-names>WH</given-names></name></person-group>
<article-title> Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly.</article-title>
<source>Am J Physiol</source>
<year>1996</year>
<volume>271</volume>
<issue>5 Pt 1</issue>
<fpage>C1424</fpage>
<lpage>C1437</lpage>
<pub-id pub-id-type="pmid">8944624</pub-id></element-citation></ref><ref id="b42-ARYA-09-326"><label>42</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Appel</surname><given-names>LJ</given-names></name><name><surname>Moore</surname><given-names>TJ</given-names></name><name><surname>Obarzanek</surname><given-names>E</given-names></name><name><surname>Vollmer</surname><given-names>WM</given-names></name><name><surname>Svetkey</surname><given-names>LP</given-names></name><name><surname>Sacks</surname><given-names>FM</given-names></name><etal></etal></person-group>
<article-title> A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group.</article-title>
<source>N Engl J Med</source>
<year>1997</year>
<volume>336</volume>
<issue>16</issue>
<fpage>1117</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="pmid">9099655</pub-id></element-citation></ref><ref id="b43-ARYA-09-326"><label>43</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Esposito</surname><given-names>K</given-names></name><name><surname>Marfella</surname><given-names>R</given-names></name><name><surname>Ciotola</surname><given-names>M</given-names></name><name><surname>Di</surname><given-names>PC</given-names></name><name><surname>Giugliano</surname><given-names>F</given-names></name><name><surname>Giugliano</surname><given-names>G</given-names></name><etal></etal></person-group>
<article-title> Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial.</article-title>
<source>JAMA</source>
<year>2004</year>
<volume>292</volume>
<issue>12</issue>
<fpage>1440</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">15383514</pub-id></element-citation></ref><ref id="b44-ARYA-09-326"><label>44</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seeram</surname><given-names>NP</given-names></name><name><surname>Henning</surname><given-names>SM</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Suchard</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Heber</surname><given-names>D</given-names></name></person-group>
<article-title> Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours.</article-title>
<source>J Nutr</source>
<year>2006</year>
<volume>136</volume>
<issue>10</issue>
<fpage>2481</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">16988113</pub-id></element-citation></ref><ref id="b45-ARYA-09-326"><label>45</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mohan</surname><given-names>M</given-names></name><name><surname>Waghulde</surname><given-names>H</given-names></name><name><surname>Kasture</surname><given-names>S</given-names></name></person-group>
<article-title> Effect of pomegranate juice on Angiotensin II-induced hypertension in diabetic Wistar rats.</article-title>
<source>Phytother Res</source>
<year>2010</year>
<volume>24</volume>
<issue>Suppl 2</issue>
<fpage>S196</fpage>
<lpage>S203</lpage>
<pub-id pub-id-type="pmid">20020514</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="t1-ARYA-09-326" position="float"><label>Table 1</label><caption><p>Acute effects of pomegranate juice on blood pressure, flow-mediated dilation, and biochemical parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Parameters</th><th rowspan="1" colspan="1">Before</th><th rowspan="1" colspan="1">After</th><th rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">SBP (mmHg)</td><td align="center" rowspan="1" colspan="1">125.38 ± 11.80</td><td align="center" rowspan="1" colspan="1">116.15 ± 7.94</td><td align="center" rowspan="1" colspan="1">0.013</td></tr><tr><td rowspan="1" colspan="1">DBP (mmHg)</td><td align="center" rowspan="1" colspan="1">82.69 ± 5.25</td><td align="center" rowspan="1" colspan="1">78.08 ± 3.25</td><td align="center" rowspan="1" colspan="1">0.010</td></tr><tr><td rowspan="1" colspan="1">FMD (%)</td><td align="center" rowspan="1" colspan="1">0.30 ± 0.17</td><td align="center" rowspan="1" colspan="1">0.36 ± 0.17</td><td align="center" rowspan="1" colspan="1">0.172</td></tr><tr><td rowspan="1" colspan="1">Hs-CRP (mg/L)</td><td align="center" rowspan="1" colspan="1">1.39 ± 1.14</td><td align="center" rowspan="1" colspan="1">1.20 ± 0.94</td><td align="center" rowspan="1" colspan="1">0.263</td></tr><tr><td rowspan="1" colspan="1">ICAM-1 (ng/mL)</td><td align="center" rowspan="1" colspan="1">297.00 ± 122.30</td><td align="center" rowspan="1" colspan="1">265.23 ± 125.35</td><td align="center" rowspan="1" colspan="1">0.248</td></tr><tr><td rowspan="1" colspan="1">VCAM-1 (ng/mL)</td><td align="center" rowspan="1" colspan="1">1008.31 ± 450.99</td><td align="center" rowspan="1" colspan="1">993.92 ± 447.42</td><td align="center" rowspan="1" colspan="1">0.657</td></tr><tr><td rowspan="1" colspan="1">E-Selectin (ng/mL)</td><td align="center" rowspan="1" colspan="1">27.77 ± 15.89</td><td align="center" rowspan="1" colspan="1">25.49 ± 14.19</td><td align="center" rowspan="1" colspan="1">0.182</td></tr><tr><td rowspan="1" colspan="1">IL-6 (ng/mL)</td><td align="center" rowspan="1" colspan="1">0.45 ± 0.16</td><td align="center" rowspan="1" colspan="1">0.46 ± 0.15</td><td align="center" rowspan="1" colspan="1">0.763</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-ARYA-09-326"><p>SBP: Systolic blood pressure; DBP: Diastolic blood pressure; FMD: Flow-mediated dilation; hsCRP: High-sensitivity C-reactive protein; ICAM-1: Intracellular adhesion molecule-1; VCAM-1: Vascular cell adhesion molecule-1; IL-6: Interleukin-6; Group comparisons were made using paired t-test (in case of normally distributed data) or Wilcoxon signed-ranks test (in case of non-normally distributed data).</p></fn></table-wrap-foot></table-wrap></floats-group></article>